【Destiny Pharma-Product XF-73】New Asian (APSIC) guidelines for prevention of surgical site infections recommend decolonisation of Staphylococcus aureus in surgical patients to prevent surgical site infections

Date:
2019-12-17
Category:
Partner News

17th December 2019– Destiny Pharma issued an announcement, which is summarized as follows: 

Destiny Pharma notes that new guidelines from the Asia Pacific Society for Infection Control (APSIC) for the prevention of surgical site infections have been published in the peer-reviewed journal, Antimicrobial Resistance and Infection Control. These guidelines underline the market potential of Destiny Pharma’s lead product XF-73 which is in Phase 2b clinical trials testing its ability to kill Staphylococcus aureus bacteria in the patient’s nose prior to surgery thereby reducing the potential for serious post-surgical bacterial infections including MRSA.

Neil Clark, Chief Executive Officer of Destiny Pharma, commented:

“This new Asian review strongly supports the potential for Destiny Pharma’s lead product, XF-73, to meet the guidelines’ clinical recommendation to prevent post-surgical infections by decolonising whilst mitigating the emergence of AMR. Previous independent publications in the US and from the World Health Organisation already support this approach. XF-73 nasal gel is currently in a Phase 2b clinical trial in the US and Europe and we look forward to reporting results in mid-2020. There is a significant commercial opportunity for XF-73, which is estimated to have potential peak annual product sales of $1 billion in the US alone.”

The APSIC guidelines also support Destiny Pharma’s strategic approach in China where it has a regional collaboration with China Medical Systems, a specialty pharmaceutical company focusing on the sale of prescription drugs and other medicinal products to all therapeutic departments in hospitals across the China region.

Original website Link:

https://otp.tools.investis.com/clients/uk/destiny_pharma_ltd/rns/regulatory-story.aspx?cid=2241&newsid=1353195